Cardionovum

Be up
to date.

Latest press release

Late-Breaking Xlimit RCT data presented at CSC Congress demonstrate an equivalent performance of the Xlimus® DES in terms of OCT derived endpoints than the Synergy™ DES.

Bonn, Germany. November 16, 2022 – Data presented at Innovation session today at the CSC 2022 congress demonstrated an equivalent performance of the Xlimus® DES in terms of OCT derived endpoints than the Synergy™ DES, including Neointimal Volume and Neointimal Volume weighted by length at 6 months. Secondary endpoints, including other OCT parameters, such as in-stent Minimum Lumen Area (MLA) and percentage of strut coverage as well as clinical endpoints, showed no significant differences between the two groups in any of the evaluated parameters within the Xlimit RCT.

Learn more >>

Prof. Matteo Tozzi discusses about new data bolster safety and effectiveness of Safepax®

Prof. Matteo Tozzi (Varese, Italy) speaks to Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting in Barcelona (Spain) about his new study that analyzes the concentrations of paclitaxel in the bloodstream after the use of a Drug-Coated Balloons (DCBs) in AVFs.

Learn more >>

CARDIONOVUM® announces regulatory approval of APERTO® OTW in Mexico

We are proud to announce that we have received the authorization by the Secretaria de Salud and COFEPRIS to distribute APERTO® OTW in Mexico.

Learn more >>

Cardionovum® announces First Procedure in Hyper II International Clinical Trial.

CARDIONOVUM® today announced the enrollment of the first patient in the International Hyper II Clinical Study

Learn more >>

CARDIONOVUM® announces the first Signature RCT patient enrollment

On June 8th, in Sankt Gertrauden hospital in Berlin, Germany, the first Signature RCT patient has been enrolled

Learn more >>

CARDIONOVUM announces completion of patients enrolment in XLIMIT Trial

Trial designed to evaluate non inferiority of XLIMUS DES vs SYNERGY EES in terms of reendothelialization assessed with OCT in patients undergoing percutaneous coronary intervention

Learn more >>

Upcoming events

Cardionovum® at PVI 2024

Cardionovum® is pleased to invite you to visit us at booth #20.

Location:

Les salles du Carrousel du Louvre
99 rue de Rivoli
75001 Paris,
France

Date: Dec 12, 2024–Dec 14, 2024

Latest events

Cardionovum® at Deutschen Gesellschaft für Kardiologie (DGK) 2023

Cardionovum® is glad to invite you to visit us at booth #017

Location:

Congress Center Rosengarten Mannheim (CCR)
Rosengartenplatz 2, 68161
Mannheim, Germany

Date: Apr 12, 2023–Apr 16, 2023

Cardionovum® is glad to invite you to attend the scientific session:

Clinical Scenario: DES, BRS & DCB - New Insights

  • Dott. Keeble will disclose his presentation entitled “DCB-alone PCI in De Novo Lesions: Exploring New Frontiers with RESTORE® DCB”

    Monday 5th December at 09:15h
    Hall H

Location:

David Intercontinental Convention Center
12 Kaufman St,
Tel Aviv, 61501 Israel

Date: Dec 05, 2022–Dec 06, 2022

Learn more >>

Cardionovum® at CSC 2022

Cardionovum® is delighted to announce the release of the XLIMIT Randomized Clinical Trial data.

  • Dr. Luca Testa, the PI of the study, will share his findings on the topic of:
    OCT-based analysis of XLIMUS® DES vs. SYNERGY DES

    Thursday 16th November at 17:45h
    SALA MADRID 1-2

Location:

Hotel Riu Plaza España
Calle Gran Vía, 84,
28013, Madrid, Spain

You are welcome to visit us at booth #2

Date: Nov 16, 2022–Nov 17, 2022

Learn more >>

go top